Welcome to our dedicated page for Iteos Therapeutics SEC filings (Ticker: ITOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iTeos Therapeutics, Inc. (ITOS) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents, including annual and quarterly reports, current reports on Form 8-K, and specialized forms related to its change in status as a public company. These filings offer detailed information on iTeos’ immuno-oncology pipeline, clinical collaborations, strategic decisions, and corporate transactions.
For investors and researchers examining iTeos, Forms 10-K and 10-Q (where available) describe the company’s business, risk factors, and financial condition, including discussion of programs such as belrestotug, EOS-984, EOS-215, and inupadenant, and its focus on the TIGIT/CD226 axis, the adenosine pathway, ENT1, TREM2, and PTPN1/2. Form 8-K filings capture material events, such as the May 2025 decision to wind down operations, the July 2025 Agreement and Plan of Merger with Concentra Biosciences, and the August 29, 2025 completion of the tender offer and merger that made iTeos a wholly owned subsidiary of Concentra.
Regulatory status changes are documented in Form 25, filed by Nasdaq on August 29, 2025, which notified the SEC of the removal of iTeos’ common stock from listing on The Nasdaq Stock Market LLC, and in Form 15, filed by iTeos on September 8, 2025 to terminate registration of its common stock under Section 12(g) of the Exchange Act and suspend reporting obligations under Sections 13 and 15(d). Together, these filings show that ITOS is no longer a listed or reporting security.
On Stock Titan, these documents are supplemented by AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major developments such as the structure of the Concentra transaction, the terms of the contingent value rights, and the implications of delisting and deregistration. Users can review historical SEC disclosures to analyze how iTeos’ clinical strategy, financial position, and corporate structure evolved leading up to its acquisition and transition from a public to a privately held company.
iTeos Therapeutics agreed to be acquired and its registered equity offerings were terminated. The company entered a Merger Agreement with Concentra Biosciences and, on August 29, 2025, merged into a Concentra subsidiary with iTeos surviving as a wholly owned subsidiary of Parent. Each outstanding common share (other than specified exclusions) was converted into $10.047 in cash and one non-transferable contingent value right. As a result, iTeos withdrew and terminated multiple Form S-8 registration statements and removed any unsold or unissued shares from registration.
iTeos Therapeutics, Inc. has filed post-effective amendments to withdraw and remove from registration any unissued and unsold shares previously registered under multiple Form S-8 registration statements. The company entered into a Merger Agreement on July 18, 2025, and on August 29, 2025 Merger Sub merged into the registrant, leaving the company as a wholly owned subsidiary of Concentra Biosciences, LLC. Each outstanding share (with specified exceptions) was converted into $10.047 in cash plus one non-transferable contractual contingent value right (CVR). As a result of the Merger, all offerings under the referenced registration statements were terminated and the registrant removed the unsold registered securities and terminated the effectiveness of the registration statements.
iTeos Therapeutics, Inc. filed post-effective amendments to withdraw and remove any unissued and unsold securities previously registered under multiple Form S-8 registration statements. The company states that on July 18, 2025 it entered into a Merger Agreement with Concentra Biosciences, LLC and its subsidiary Merger Sub, and that on August 29, 2025 Merger Sub was merged into iTeos with iTeos surviving as a wholly owned subsidiary of Parent. In the Merger each outstanding common share (with limited exceptions) converted into $10.047 in cash plus one non-transferable contractual contingent value right (CVR). As a result, all offerings under the listed registration statements were terminated and the registrant removed the unsold registered securities from registration.
iTeos Therapeutics, Inc. completed a merger and terminated pending equity offerings. The company entered into a Merger Agreement with Concentra Biosciences, LLC and its subsidiary, and on August 29, 2025 Merger Sub merged into iTeos with iTeos surviving as a wholly owned subsidiary of Parent. In the transaction each outstanding share (excluding treasury shares, shares held by Parent/Merger Sub, and shares subject to valid appraisal) was converted into $10.047 in cash per share plus one non-transferable contractual contingent value right (CVR) per share. As a result of the Merger, iTeos terminated its registered offerings and filed post-effective amendments to withdraw and remove any unsold securities previously registered under several Form S-8 registration statements.
iTeos Therapeutics completed a merger and withdrew its outstanding S-8 registration statements. The company entered into a Merger Agreement with Concentra Biosciences, LLC and on August 29, 2025 Merger Sub merged into iTeos, leaving iTeos as a wholly owned subsidiary of Parent. Each outstanding share of common stock (other than treasury shares, Parent/Merger Sub-owned shares and properly exercised appraisal shares) converted into $10.047 in cash plus one non-transferable contractual contingent value right (CVR). As a result of the Merger, iTeos terminated all offerings under the listed Registration Statements and filed post-effective amendments to remove any unissued and unsold securities and to terminate the effectiveness of those Registration Statements.
iTeos Therapeutics, Inc. has filed post-effective amendments to withdraw and remove all unissued and unsold securities previously registered under multiple Form S-8 registration statements for its 2019, 2020 equity plans.
Separately, the company entered into a Merger Agreement with Concentra Biosciences, LLC and completed a merger in which iTeos became a wholly owned subsidiary of Concentra. Each outstanding share (other than specified exclusions) was converted into $10.047 in cash per share plus one non-transferable contractual contingent value right. As a result of the Merger, the registrant terminated all offerings and removed the remaining registered but unsold plan securities from registration.
Nasdaq has submitted a Form 25 notifying the SEC of the removal of iTeos Therapeutics, Inc. (ITOS) from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office at 321 Arsenal Street, Watertown, Massachusetts and provides a contact phone number. The form states the Exchange and the issuer have complied with applicable rule provisions governing withdrawal or removal, but the specific rule selection box, signature and date fields are not completed in the provided content.
iTeos Therapeutics, Inc. has been acquired by Concentra Biosciences through a tender offer and follow-on merger. Stockholders received $10.047 in cash per share plus one non-transferable contingent value right (CVR) per share, providing potential future payments under a CVR agreement.
The tender offer expired on August 28, 2025, with 32,226,407 shares validly tendered, representing about 72.17% of outstanding shares, satisfying the minimum tender condition. On August 29, 2025, a merger under Delaware law made iTeos a wholly owned subsidiary of Concentra, and remaining shares were converted into the same cash-and-CVR consideration.
Trading in iTeos common stock on Nasdaq was suspended, and delisting and deregistration procedures have been initiated. As part of the change in control, the prior board members resigned at the merger’s effective time, and the directors and officers of the acquirer’s merger subsidiary, led by Kevin Tang, became the leadership of the surviving corporation.
iTeos Therapeutics filed an amendment to its Schedule 14D-9 regarding the tender offer by Concentra Biosciences to acquire all outstanding common shares. The Offer Price is specified as $10.047 per share in cash plus one non-transferable contractual contingent value right (CVR) per share. The amendment references the Offer to Purchase and Letter of Transmittal dated August 1, 2025, and the filing is signed by President and CEO Michel Detheux, Ph.D.
iTeos Therapeutics (ITOS): Reporting persons report zero ownership as of June 30, 2025. Multiple related entities and Mark N. Lampert filed Amendment No. 2 to Schedule 13G stating that, at the close of business on June 30, 2025, the Reporting Persons no longer beneficially owned any shares of iTeos Therapeutics common stock (CUSIP 46565G104). The filing lists each reporting entity, its jurisdiction, and confirms 0 shares held, 0% of the class. The signatures indicate Mark N. Lampert signed on behalf of each Reporting Person on August 14, 2025.
FAQ
What is the current stock price of Iteos Therapeutics (ITOS)?
What is the market cap of Iteos Therapeutics (ITOS)?
